HIV Infections Clinical Trial
Official title:
Culture-Specific Neurodevelopmental Assessment of HIV-affected Children
Verified date | March 2024 |
Source | Michigan State University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The investigators will use Brain Power Games or Village Builder, two different MSU-developed computer-based learning games for children on Tablets, as a neurocognitive "stress test" or medical "challenge" test, in order to evaluate brain/behavior functional integrity in HIV-affected children. This dual use of BPG is a key innovative feature. Each of the 5 core BPG games lasts 10 minutes and trains fine motor, monitoring/attention, visual/auditory working memory, spatial navigational learning. Village Builder (VB) uses similar graphics as BPG, but is a pro-social "world-building" game where children gather and protect resources to build a village. thus VB emphasizes planning/reasoning (executive function or EF) neurocognitive abilities, while BPG emphasizes attention, memory, and learning tasks. In As an African child plays with BPG or VB on a touch-screen tablet, we will use games as a dynamic window into the child's developing brain and EF-based frontal lobe development Aim 1. Evaluate concurrent and predictive validity of BPG static (baseline) and dynamic (during 12 training sessions) cognitive assessments Aim 2. Compare the validity of BPG static and dynamic assessments Aim 3. Test the sensitivity of dynamic assessment to learning loss over time by evaluating how much BPG and/or VB performance gains diminish during a 6-month absence of training The investigator's central hypothesis is that the BPG and VB performance gains (dynamic assessment) will explain the additional variation in the gold-standard measures at time points after static (baseline) assessment, and more effectively capture the effects of HIV/ARV exposure and treatment across HIV affected cohorts (HIV, HEU, HUU) of children in Uganda and Malawi.
Status | Active, not recruiting |
Enrollment | 600 |
Est. completion date | December 23, 2025 |
Est. primary completion date | February 29, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 12 Years |
Eligibility | Inclusion Criteria: - HEU and HUU children at least 5 yrs of age and older from the PROMISE ND study (Uganda and Malawi) - HIV+ children from P1104s (Uganda and Malawi) - HUU children age-matched from PROMISE ND and P1104s study cohorts (Uganda and Malawi) Exclusion Criteria: - Medical history of serious birth complications - Severe malnutrition - Bacterial meningitis - Encephalitis - Cerebral malaria - Other known brain injury or disorder requiring hospitalization - Seizures or other neurological disabilities |
Country | Name | City | State |
---|---|---|---|
Malawi | Johns Hopkins Research Project | Blantyre | |
Uganda | Makerere University Johns Hopkins University Research Collaboration | Kampala |
Lead Sponsor | Collaborator |
---|---|
Michigan State University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Johns Hopkins University, Kamuzu University of Health Sciences, MU-JHU CARE, University of Michigan |
Malawi, Uganda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Kaufman Assessment Battery for Children 2nd Ed (KABC-II) scores | the KABC-II will be the principal test for cognitive ability.47 It is validated in sub-Saharan Africa48-51 and has been adapted for pediatric HIV research.1,18,46,52-55 Using the Luria model for neuropsychological assessment within KABC-II, the primary outcome variables are the global scores of Sequential Processing (memory), Simultaneous Processing (visual-spatial processing and problem solving), Learning (immediate and delayed memory), Planning (executive reasoning), Delayed Recall, Nonverbal Index (NVI) subtests not dependent on understanding instructions in English, and Mental Processing Index (MPI), a composite of all the cognitive performance areas. | Baseline, 3 months, and 6 months follow-up | |
Secondary | Change in Test of Variables of Attention (TOVA) scores | TOVA is a computerized visual continuous performance test used in to screen, diagnose and monitor children and adults at risk for ADHD.56 TOVA consists of the rapid (tachistoscopic) presentation of a large geometric square on the computer screen with a smaller dark box either in the upper position (signal) or lower position (non-signal). The child is asked to press a switch held in the preferred hand as fast as possible in response to the signal (measuring vigilance attention), but to withhold responding to the non-signal (measuring impulsivity). | Baseline, 3 months, and 6 months follow-up | |
Secondary | Change in CogState scores | CogState presents a 30-min session that includes playing cards in a game-like manner to assess memory, attention, discrimination learning, and executive function that is non-language dependent. CogState tests include Card Detection (simple reaction time), Identification (choice reaction time), One-Back Working Memory, and One-Card Learning. CogState also includes the Groton Maze Task, which can measure visual-motor tracking (Maze Chase) and executive functioning/planning (Maze Learning). | Baseline, 3 months, and 6 months follow-up | |
Secondary | Change in Achenbach Child Behavior Checklist (CBCL) scores | Parent-based screening tool for emotional and behavioral problems observed in the child. CBCL is important to assess when a child's social environment is enriched by adult oversight in game assessment and training, reflecting a collateral training benefit | Baseline, 3 months, and 6 months follow-up | |
Secondary | Change in Caldwell Home Observation for the Measurement of the Environment (HOME) scores | We will use the middle childhood version of the Caldwell Home Observation for the Measurement of the Environment (HOME) validated for use as an important distal measure predictive of our gold standard assessments.The HOME assesses the stimulation and learning opportunities offered by the child's home environment. | Baseline, 3 months, and 6 months follow-up | |
Secondary | Change inCD4+ T-cell counts (HIV cohort only) | As part of their standard of care (HIV cohort only), CD4 measures will be available from a blood draw taken within a week from the time of neuropsychological assessment as a more proximal predictor of disease effects on assessment performance | Baseline, 3 months, and 6 months follow-up | |
Secondary | Change in viral load (HIV cohort only) | As part of their standard of care (HIV cohort only), viral load will be available from a blood draw taken within a week from the time of neuropsychological assessment as a more proximal predictor of disease effects on assessment performance | Baseline, 3 months, and 6 months follow-up | |
Secondary | Change in CD8 cell count (HIV cohort only) | As part of their standard of care (HIV cohort only), CD8 measures will be available from a blood draw taken within a week from the time of neuropsychological assessment as a more proximal predictor of disease effects on assessment performance | Baseline, 3 months, and 6 months follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |